Gestational Diabetes Guidelines Compared: ADA, ACOG, AACE, Endocrine Society, and USPSTF

What Is Gestational Diabetes and Why Do the Guidelines Disagree?

Gestational diabetes is a form of glucose intolerance that appears or is first recognized during pregnancy. It affects between 7 and 10 percent of U.S. Pregnancies, though some estimates using the International Association of Diabetes and Pregnancy Study Groups (IADPSG) one-step criteria put the figure even higher. The condition carries real stakes: untreated GDM raises the risk of macrosomia, preeclampsia, cesarean delivery, neonatal hypoglycemia, and your own long-term risk of type 2 diabetes.

The guideline disagreement is not academic squabbling. It is a direct consequence of one landmark trial producing numbers that, if adopted globally, would more than double the diagnosed population overnight.

The HAPO Trial: Where the Disagreement Starts

The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study enrolled 23,316 pregnant women across nine countries and demonstrated a continuous, linear relationship between maternal glucose at 24 to 28 weeks and adverse outcomes, with no obvious threshold. The IADPSG used HAPO data to set new one-step diagnostic cutoffs in 2010, which the ADA incorporated. ACOG reviewed the same data and concluded the evidence was insufficient to recommend universal adoption of a one-step approach, primarily because of cost, workload, and uncertainty about whether treating milder cases actually improved outcomes at a population level.

One-Step vs. Two-Step: The Core Split

The fundamental fork in the road is whether you do one test or two.

Two-step approach (ACOG, USPSTF preferred): A 50-gram, one-hour glucose challenge test (GCT) is given first, non-fasting. If the one-hour value meets the threshold (most commonly 130 or 140 mg/dL depending on the lab), a 100-gram, three-hour fasting OGTT follows. GDM is diagnosed if two or more values on the three-hour OGTT meet the Carpenter-Coustan or National Diabetes Data Group cutoffs.

One-step approach (IADPSG, ADA option, Endocrine Society): A 75-gram, two-hour fasting OGTT is given to all pregnant women at 24 to 28 weeks. GDM is diagnosed if any single value meets the threshold.

The USPSTF 2021 recommendation concludes that screening for GDM after 24 weeks is supported by adequate evidence, but deliberately declines to specify which approach clinicians must use, noting the ongoing debate. ACOG Practice Bulletin 190 continues to endorse the two-step approach as the standard in the United States.

Diagnostic Cutoffs by Society: A Side-by-Side Look

The numbers below explain why the same woman could test positive under one set of criteria and negative under another.

Two-Step Criteria (ACOG / Carpenter-Coustan)

Under ACOG's preferred Carpenter-Coustan thresholds, GDM requires two or more of the following on the 100g, three-hour OGTT:

| Time Point | Carpenter-Coustan | NDDG | |---|---|---| | Fasting | <95 mg/dL | <105 mg/dL | | 1 hour | <180 mg/dL | <190 mg/dL | | 2 hour | <155 mg/dL | <165 mg/dL | | 3 hour | <140 mg/dL | <145 mg/dL |

Two or more values at or above the cutoff = GDM diagnosis.

One-Step Criteria (IADPSG / ADA Option / Endocrine Society)

The ADA 2024 Standards of Care in Diabetes endorse both approaches but present the IADPSG one-step 75g cutoffs as follows: fasting <92 mg/dL, one-hour <180 mg/dL, two-hour <153 mg/dL. Any single abnormal value is sufficient for diagnosis. The Endocrine Society's 2013 clinical practice guideline similarly supports the one-step IADPSG approach, citing the continuous risk relationship from HAPO.

What the Difference Means for You

A woman with a fasting glucose of 93 mg/dL on a 75g OGTT would be diagnosed under IADPSG/ADA one-step criteria. Under the two-step approach, she might not reach that stage at all, or might have only one abnormal value on the three-hour test, which is insufficient for a two-step diagnosis. This is not a trivial difference: a 2014 NIH Consensus Panel estimated that adopting the one-step criteria would increase GDM prevalence from roughly 5 to 18 percent of pregnancies.

Who Is Screened and When: Risk Stratification Across Guidelines

All major U.S. Guidelines agree on 24 to 28 weeks as the primary screening window for women without known pre-existing diabetes. Where they differ is on early screening.

Early Screening for High-Risk Women

The ADA 2024 Standards recommend testing women with risk factors for undiagnosed type 2 diabetes at the first prenatal visit using standard diagnostic criteria (not GDM-specific cutoffs). Risk factors include BMI >25 kg/m² (or >23 kg/m² in Asian American women), a prior GDM pregnancy, PCOS, a first-degree relative with diabetes, or a history of delivering a baby over 9 pounds.

ACOG's guidance similarly notes that women with multiple risk factors may warrant early glucose assessment, though the specific trigger thresholds vary by clinical judgment.

PCOS: A Condition That Changes Your GDM Risk Substantially

If you have polycystic ovary syndrome, your baseline insulin resistance means your GDM risk is two to three times higher than in women without PCOS. The Endocrine Society and ACOG both acknowledge this elevated risk. Some clinicians with expertise in PCOS perform glucose assessment at the first prenatal visit rather than waiting until 24 weeks, though no guideline has formally mandated this as a universal standard. This is an area where the evidence in women with PCOS specifically remains thinner than it should be, and current practice recommendations are extrapolated from general high-risk guidance rather than PCOS-specific RCT data.

Blood Glucose Targets During Pregnancy: Where the Numbers Differ

Getting glucose into range is the central therapeutic goal. The targets are close across guidelines but not identical, and the differences matter at the margins.

ADA 2024 Glucose Targets in GDM

The ADA recommends:

• Fasting: <95 mg/dL
• One-hour postprandial: <140 mg/dL
• Two-hour postprandial: <120 mg/dL

AACE/Endocrine Society Targets

The AACE 2023 Diabetes Management Algorithm and Endocrine Society guidance set slightly tighter fasting targets:

• Fasting: <90 mg/dL
• One-hour postprandial: <140 mg/dL
• Two-hour postprandial: <120 mg/dL

The five mg/dL difference in the fasting target is small in absolute terms but may push more women toward insulin initiation under AACE-aligned practice compared to ADA-aligned practice.

CGM in GDM: An Emerging Area

Continuous glucose monitoring (CGM) is gaining traction in GDM management. The CONCEPTT trial, though primarily conducted in women with type 1 diabetes in pregnancy, demonstrated that CGM use reduced neonatal intensive care admissions. For GDM specifically, the data are still maturing. The ADA notes CGM may be considered in GDM managed with insulin, but no major guideline has yet made it a standard requirement. Expect this area to evolve as GDM-specific CGM trial data accumulate.

Treatment: Medical Nutrition Therapy, Insulin, and the Metformin Debate

Medical Nutrition Therapy and Physical Activity First

Every guideline starts here. Medical nutrition therapy (MNT) controls glucose in approximately 70 to 85 percent of GDM cases without medication. A registered dietitian with prenatal experience typically designs a carbohydrate-controlled meal plan (generally 175 grams of carbohydrate minimum per day, distributed across three meals and two to three snacks) alongside 30 minutes of moderate aerobic activity on most days, per ADA guidance.

When Glucose Targets Are Not Met: Insulin Is First-Line

If MNT and activity fail to achieve targets within one to two weeks, medication is indicated. All four major guidelines, ADA, ACOG, AACE, and the Endocrine Society, designate insulin as the preferred first-line pharmacological agent in GDM. Insulin does not cross the placenta in clinically meaningful amounts at therapeutic doses, which makes its safety profile in pregnancy clearer than any oral agent.

The ADA 2024 Standards specifically state that insulin is the preferred agent for GDM when pharmacotherapy is required, and that both metformin and glyburide have limitations as alternatives.

Metformin in GDM: What the Evidence Actually Shows

Metformin crosses the placenta. Fetal cord blood concentrations reach approximately 50 percent of maternal levels. This is the core concern that separates expert opinion.

The MiG (Metformin in Gestational Diabetes) trial randomized 751 women and found metformin did not increase perinatal complications compared to insulin, and women preferred it. That sounds reassuring. The follow-up MiG TOFU data, however, raised a signal: children exposed to metformin in utero had greater total and visceral fat mass at age 2, and at age 9 had higher BMI and waist circumference compared to insulin-exposed peers. This finding has not been replicated in all cohorts, but it explains why ACOG's guidance categorizes metformin as an acceptable alternative when insulin is refused or not available, rather than an equivalent first choice.

The Endocrine Society takes a similar position. Women who take metformin for PCOS before pregnancy are typically counseled to continue through the first trimester for miscarriage risk reduction, then transition to insulin if GDM is diagnosed. That nuance matters if you are entering pregnancy on metformin.

Glyburide: Largely Falling Out of Favor

Glyburide crosses the placenta more than early data suggested. A 2015 meta-analysis in Obstetrics and Gynecology found that glyburide was associated with higher rates of neonatal hypoglycemia and macrosomia compared to insulin. Both ACOG and the ADA now note glyburide should not be used as a first-line agent, and the Endocrine Society largely concurs. It is not listed as a recommended option in current ADA Standards.

Postpartum Management: The Step Most Women Miss

The conversation about GDM does not end at delivery. This is where every major guideline agrees loudly, and where real-world follow-through is weakest.

The 50 Percent Lifetime Risk of Type 2 Diabetes

Women who have had GDM face approximately a 50 percent lifetime risk of developing type 2 diabetes, with the steepest conversion rate occurring in the first five years postpartum. That risk is further amplified by PCOS, elevated pre-pregnancy BMI, and a family history of diabetes.

What Each Guideline Recommends Postpartum

ADA: A 75g OGTT at 4 to 12 weeks postpartum, using non-pregnant diagnostic thresholds (not GDM cutoffs). If normal, rescreen every one to three years thereafter with an HbA1c, fasting glucose, or OGTT.

ACOG: 75g OGTT at 4 to 12 weeks postpartum, then at minimum every three years. ACOG emphasizes that the HbA1c alone may miss impaired glucose tolerance in the postpartum period.

AACE/Endocrine Society: Align with ADA on the 4 to 12 week postpartum OGTT and longer-term annual or biennial screening.

USPSTF: The 2021 recommendation notes that postpartum rescreening is clinically important but does not grade a separate postpartum screening recommendation.

The Breastfeeding Window: A Metabolic Opportunity

Breastfeeding reduces postpartum glucose levels and is associated with lower rates of T2D conversion after GDM. A 2015 cohort study in Annals of Internal Medicine found that lactation duration of at least two months was associated with significantly lower T2D incidence over a two-year follow-up. ACOG and the ADA both encourage breastfeeding in women with a history of GDM, not only for infant benefits but for your own metabolic health. Metformin is detectable in breast milk but at very low levels; most guidelines categorize it as likely compatible with breastfeeding, though insulin remains the unequivocal choice if pharmacotherapy continues postpartum.

Who Is This Condition Most Relevant For, by Life Stage

Reproductive Years (Trying to Conceive or Early Pregnancy)

If you have PCOS, obesity (BMI >30), or a prior GDM pregnancy, pre-conception counseling with glucose optimization reduces your risk. An HbA1c below 6.5 percent before conception is the ADA's preferred benchmark to distinguish undiagnosed T2D from GDM risk at the first prenatal visit.

During Pregnancy

The 24 to 28 week window is your primary diagnostic window. Know which screening approach your obstetric provider uses and what cutoffs they apply. If your provider uses one-step IADPSG criteria, your diagnosis threshold is lower than under two-step Carpenter-Coustan criteria.

Perimenopause and Post-Menopause

A history of GDM is a flag your internist or gynecologist should know about permanently. Estrogen changes at perimenopause shift insulin sensitivity further, increasing conversion risk. Women with prior GDM entering perimenopause warrant annual fasting glucose or HbA1c screening, not the standard three-year interval used for the general population. This is an area where current guidelines give insufficient specific guidance, and the clinical community extrapolates from general T2D prevention evidence.

Comparing the Guidelines: A Quick Reference Table

| Domain | ADA 2024 | ACOG PB 190 | AACE / Endocrine Society | USPSTF 2021 | |---|---|---|---|---| | Screening approach | Both (one-step or two-step) | Two-step preferred | One-step IADPSG preferred | Either; no mandate | | Screening window | 24-28 wks (earlier if risk) | 24-28 wks (earlier if risk) | 24-28 wks | After 24 wks | | Fasting glucose target | <95 mg/dL | <95 mg/dL | <90 mg/dL | Defers to ADA/ACOG | | First-line Rx | Insulin | Insulin | Insulin | Insulin | | Metformin stance | Acceptable alternative | Acceptable alternative | Acceptable alternative (2nd line) | No stance | | Postpartum OGTT | 4-12 wks | 4-12 wks | 4-12 wks | Recommends rescreening | | Long-term rescreening | Every 1-3 years | Every 1-3 years | Annual or biennial | Not graded |

Insulin Regimens in GDM: What Pregnancy Changes

Insulin requirements in GDM are not static. Placental hormones, particularly human placental lactogen, progesterone, and cortisol, drive progressive insulin resistance through the second and third trimesters. This means your dose will likely increase as pregnancy advances.

Common Regimens

Intermediate-acting NPH insulin overnight targets fasting hyperglycemia. Rapid-acting insulin (insulin lispro or insulin aspart, both of which have FDA-labeling supporting use in pregnancy) is added at meals when postprandial readings are elevated. Human regular insulin is an alternative with a longer track record but slower onset.

Insulin glargine (Lantus) and insulin detemir (Levemir) are used in some practices for GDM, though their evidence base in GDM specifically is thinner than NPH. The Endocrine Society guideline notes that detemir may be preferred over glargine in pregnancy based on a randomized trial showing non-inferior control, though glargine is more commonly used in practice.

Sex-Specific PK Note

Women's body composition, renal clearance, and volume of distribution shift significantly across gestation. Insulin sensitivity drops by roughly 50 percent between early and late pregnancy in women with GDM, meaning the dose that controlled glucose at 26 weeks may be inadequate by 34 weeks. Frequent monitoring and dose titration, typically every one to two weeks in the third trimester, are standard.

A Practical Framework for Discussing Guidelines With Your Provider

Most prenatal practices follow a single guideline set without explaining the choice to patients. Knowing what to ask can change the conversation.

Ask your provider:

1. "Are you using one-step or two-step screening, and what cutoffs?"
2. "If I'm diagnosed, what glucose targets are you aiming for, fasting and postprandial?"
3. "If I need medication, will you start insulin directly, or consider metformin first, and why?"
4. "When will you schedule my postpartum OGTT, and who will follow up on long-term rescreening?"

These four questions map onto the exact domains where guidelines diverge. A provider who can answer all four specifically, with numbers, is practicing evidence-based GDM care.

The Endocrine Society states directly in its clinical practice guideline: "We recommend that all pregnant women not previously known to have diabetes undergo a 75-g 2-hour OGTT at 24 to 28 weeks of gestation." ACOG counters that "the two-step approach is the recommended approach in the United States." Your provider's choice of guideline will determine whether you are screened once or twice, and what thresholds trigger your diagnosis.

Women deserve to know that both positions exist, that neither is definitively "wrong," and that the NIH 2013 Consensus Panel could not reach agreement after systematic review. That is intellectual honesty, not clinical uncertainty you need to fear.